These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2371973)

  • 1. Ki-67 labeling index is a more reliable measure of solid tumor proliferative activity than tritiated thymidine labeling.
    Deshmukh P; Ramsey L; Garewal HS
    Am J Clin Pathol; 1990 Aug; 94(2):192-5. PubMed ID: 2371973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidine labeling index and Ki-67 growth fraction in lesions of the breast.
    Kamel OW; Franklin WA; Ringus JC; Meyer JS
    Am J Pathol; 1989 Jan; 134(1):107-13. PubMed ID: 2536520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunocytochemical staining of proliferating cells in endoscopically biopsied tissues of gastric carcinomas with monoclonal antibody Ki-67.
    Yonemura Y; Kimura H; Ooyama S; Kamata T; Yamaguchi A; Matsumoto H; Ninomiya I; Miyazaki I
    Oncology; 1991; 48(2):162-5. PubMed ID: 1997941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of tumor cell kinetics by monoclonal antibody Ki-67.
    Yonemura Y; Ohoyama S; Kimura H; Kamata T; Yamaguchi A; Miyazaki I
    Eur Surg Res; 1990; 22(6):365-70. PubMed ID: 2079097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the thymidine labeling and Ki-67 proliferative indices in 126 breast cancer patients.
    Molino A; Pedersini R; Micciolo R; Frisinghelli M; Giovannini M; Pavarana M; Nortilli R; Santo A; Manno P; Padovani M; Piubello Q; Cetto GL
    Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):304-9. PubMed ID: 12607597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cell kinetic investigations in fibrocystic mastopathies and invasive breast carcinomas].
    Kunz J
    Acta Histochem Suppl; 1990; 39():175-9. PubMed ID: 2080259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of the Tritiated Thymidine Labeling Index in breast cancers.
    Araki K; Kimura M; Sakamoto K; Nishimura R; Akagi M
    Jpn J Surg; 1985 Mar; 15(2):144-9. PubMed ID: 4010096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical demonstration of DNA polymerase alpha in human brain-tumor cells.
    Kunishio K; Mishima N; Matsuhisa T; Tsuno K; Matsumi N; Satoh T; Matsumoto K; Furuta T; Nishimoto A; Shiraishi T
    J Neurosurg; 1990 Feb; 72(2):268-72. PubMed ID: 1967302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of the thymidine labeling index in squamous cell carcinoma of the head and neck.
    Greenberg B; Woo L; Blatchford S; Aguirre M; Garewal H
    Laryngoscope; 1988 Jun; 98(6 Pt 1):668-70. PubMed ID: 3374244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferative activity of human solid tumors evaluated by thymidine labeling index and primer-dependent alpha-DNA polymerase.
    Alama A; Conte PF; Di Marco E; Favoni RE; Nicolin A
    Oncology; 1986; 43(6):385-9. PubMed ID: 3808572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidine labeling index, flow cytometric S-phase measurement, and DNA index in human tumors. Comparisons and correlations.
    Meyer JS; Coplin MD
    Am J Clin Pathol; 1988 May; 89(5):586-95. PubMed ID: 3358366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measures of tumor proliferative activity.
    Brooks DJ; Garewal HS
    Int J Clin Lab Res; 1992; 22(4):196-200. PubMed ID: 1361373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reliability of 3H-thymidine labeling index: cell proliferation of colorectal carcinoma in three different centers.
    Ponz de Leon M; Costa A; Lanza G; Scalmati A; Roncucci L; Faranda A; Di Gregorio C; Fante R; Colella G; Silvestrini R
    Mod Pathol; 1991 Sep; 4(5):627-31. PubMed ID: 1758875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCNA immunopositivity index as a substitute to 3H-thymidine pulse-labeling index (TLI) in methanol-fixed human lymphocytes.
    Galand P; Del Bino G; Morret M; Capel P; Degraef C; Fokan D; Feremans W
    Leukemia; 1995 Jun; 9(6):1075-84. PubMed ID: 7596173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody. A quantitative immunohistochemical study.
    Smolle J; Soyer HP; Kerl H
    Am J Dermatopathol; 1989 Aug; 11(4):301-7. PubMed ID: 2774099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features.
    Veronese SM; Gambacorta M
    Am J Clin Pathol; 1991 Jan; 95(1):30-4. PubMed ID: 1987749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms.
    Goldblum JR; Shannon R; Kaldjian EP; Thiny M; Davenport R; Thompson N; Lloyd RV
    Mod Pathol; 1993 Nov; 6(6):663-8. PubMed ID: 7508113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody Ki-67: its use in histopathology.
    Brown DC; Gatter KC
    Histopathology; 1990 Dec; 17(6):489-503. PubMed ID: 2076881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between Ki-67 positive cells, growth rate and histological type of human intracranial tumors.
    Patsouris E; Stocker U; Kallmeyer V; Keiditsch E; Mehraein P; Stavrou D
    Anticancer Res; 1988; 8(4):537-44. PubMed ID: 3052245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma.
    Sittel C; Eckel HE; Damm M; von Pritzbuer E; Kvasnicka HM
    Laryngoscope; 2000 Jun; 110(6):1012-7. PubMed ID: 10852523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.